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The article by Cohen et al.
1 raises important issues and
provides a useful synopsis of published studies on schizo-
phrenia outcomes in 11 low- and middle-income coun-
tries. The authors use this material to challenge what
they claim to be an ‘‘axiom’’ (ie, a self-evident proposi-
tion requiring no proof) of better course and outcome
in developing countries which has been ‘‘embraced’’
by international psychiatry. They impute the origin of
this belief primarily to World Health Organization
(WHO)–led international collaborative research con-
ductedover the past 30 years
2–5and caution that the pub-
lication of the final report from the International Study
of Schizophrenia (ISoS)
6 might even further bolster con-
victions in the ‘‘better prognosis’’ hypothesis. Based on
evidence from research conducted outside the WHO
studies, they conduct a reexamination of the axiom.
Having been directly involved with the WHO schizo-
phrenia research program over decades, we wish to point
out that Cohen et al
1 have misunderstood key aspects of
the design and conclusions of the WHO studies. They
claim that ‘‘the sampling methods utilized in the WHO
studiesmayhaveresultedinoverlyoptimisticperceptions
of course and outcome’’ because ‘‘case-finding methods
whichfocusexclusivelyonhelp-seekingagencieswill miss
large proportions of seriously ill, poor prognosis individ-
uals.’’ They state, mistakenly, that the WHO studies pro-
vide no evidence allowing an evaluation of ‘‘the quality
of family and social interactions,’’ and impute to them by
implicating a view that ‘‘scarcity’’ of care resources is
responsible for better outcomes. Because these claims re-
peat an earlier critique of the WHO 10-country study
(Determinants of Outcome of Severe Mental Disorders
[DOSMeD]
4) by Edgerton and Cohen in 1994,
7 which
was answered by us in a publication
8 not quoted in the
present article, we summarize briefly the relevant fea-
tures, findings, and conclusions of that study.
An unexpected finding of the follow-up stage of the
WHO International Pilot Study of Schizophrenia
(IPSS)
3 was a markedly better overall outcome of schizo-
phrenia patients in India and Nigeria at 2-year and
5-year follow-up. Because the IPSS cohort was not nec-
essarilyrepresentativeandthefindingcouldbeanartifact
of selection, a second, epidemiologically designed study
was launched in the early 1980s. DOSMeD
4 was the first
large-scale study in which a unified design, stringent
methods, and standardized instruments were concur-
rently applied to first-episode incident cohorts (total study
population = 1379) at 12 research sites in diverse sociocul-
tural settings (Colombia, Czechoslovakia, Denmark, In-
dia, Ireland, Japan, Nigeria, Russia, United Kingdom,
and United States). The cohorts were recruited by
2-year active case finding within defined geographical
areas, aiming to intercept all new onsets at all kind of
facilities—not just mental health services, but including
primary care, police/prisons, traditional healers, and re-
ligious shrines (notably, 28% of the cases in India and
Nigeria were recruited through such ‘‘alternative’’ care
sources). For 86% of the cases, the duration of untreated
psychosis was less than 1 year, and only 10% had been
prescribed antipsychotic drugs prior to entry into the
study. Repeated ‘‘leakage’’ checks on the completeness
ofcasefindingfoundthatonlyahandfulofincidentcases
had been missed by this technique, thus categorically rul-
ingoutanascertainmentbiasfavoringinclusionofmilder
or good prognosis cases. Patients and key informants
were interviewed at baseline and at 1-year and 2-year fol-
low-up (78.2% of the cohort), and a large proportion of
the original cohort was traced and assessed again at 15
years (as part of the ISoS
6) in 8 of the 12 field research
centers. Throughout the study, high intra- and intercen-
terreliabilityofassessment usingthe PresentState Exam-
ination (PSE)
9 was maintained by joint rating of live and
prerecorded interviews. Diagnostic stringency was en-
suredbyprocessingofthePSEdatausingacomputerized
diagnostic algorithm.
9 During the first 2 years, nested
studies were conducted on the impact of potential precip-
itants of psychotic relapse: stressful life events
10 (in 10 of
the centers) and expressed emotion
11 (in Chandigarh,
India). These studies did provide important information
on family and social interactions. Operationally defined
measures of course and outcome included 1 categorical
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253index (pattern of course) and 6 quantitative dimensions
(cumulative percentages): estimated follow-up time in
psychoticepisodes,incompleteorincompleteremissions,
duration of unimpaired community functioning, time in
hospital, and time on antipsychotic medication. In all
centers, disability and social functioning were evaluated
using the WHO-Disability Assessment Schedule inter-
view. Importantly,ouranalysisdidnotconflatemeasures
of clinical status and measures of social functioning.
Analysis of predictors of outcome was based on log-
linear models (log-odds) which tested 25 potential predic-
tors against the 7 outcome variables.
The essence of the findings and conclusions of the
study are best conveyed by quoting from the DOSMeD
final report.
4 The study demonstrated clearly a diversity
of outcomes but ‘‘did not identify any particular pattern
in the course and outcome of schizophrenic illnesses
which could be regarded as specific to a given area or cul-
ture.’’ The outcome of patients in the developing coun-
tries was not uniformly better, as compared to the
outcomeindevelopedcountries.Whilehighratesofcom-
plete clinical remission were significantly more common
in developing country areas (37%) than in developed
countries (15.5%), the proportions of continuous unre-
mitting illness (11.1% and 17.4%) did not differ signifi-
cantly across the 2 types of setting. Patients in
developing countries experienced significantly longer
periods of unimpaired functioning in the community,
although only 16% of them were on continuous anti-
psychotic medication (compared with 61% in the devel-
oped countries). Across all centers, the best predictors (P
< .001) ofoutcome were type ofonset (insidious vsacute)
and type of setting (developed vs developing country),
followed by marital status (P < .01) gender (P < .05),
social isolation (P < .05), and drug abuse (P < .05). Nei-
ther type of family household (extended vs nuclear) nor
experienced avoidance by others (a putative marker of
stigma) reached statistical significance as predictor of
outcome.
Having excluded a number of potential confounders,
we concluded that ‘‘it is unlikely that the variation in
course and outcome could be reduced to a single vari-
able’’ and considered ‘‘the possibility that the clinical
conditions meeting the inclusion criteria of the study
in the 2 types of setting may be heterogeneous and
include varying proportions of etiologically and geneti-
cally different disorders which may be indistinguishable
from one another at the level of the phenotype.This
possibility exists but it cannot be properly examined
or tested at the present time, in the absence of es-
tablished genetic markers, indicators of etiology, or
other underlying mechanisms of disease.’’ Nevertheless,
‘‘a strong case can be made for a real pervasive influence
of a powerful factor which can be referred to as ‘‘cul-
ture,’’ as the context in which gene-environment interac-
tions shape the clinical picture of human disease.The
contribution of the present study is not in providing
the answer but in clearly demonstrating the existence
of the question.’’
4
Cohen et al
1 cite and review a number of non-WHO
studies in low- and middle-income countries as providing
evidence that is contrary to the ‘‘presumed wisdom’’ alleg-
edly promoted by the WHO reports. Yet they note the
‘‘heterogeneity in types of samples, follow-up periods,
and outcome measures’’ used in those studies, acknowl-
edge that no meta-analyses were possible, and base their
reasoning on ‘‘reading of the research reports, tabulations
of the available data, and interpretations of the evidence.’’
Using the same method in our perusal of Tables 3 and 5 in
the target article, we are unable to find in this literature
evidence contradicting any of the DOSMeD and ISoS
findings andconclusions. In fact, notwithstandingthe het-
erogeneity of the data due to design, methods, and power,
nearly all studies report extraordinarily high proportions
of ‘‘complete recovery,’’ ‘‘no or minimal psychotic symp-
toms,’’ ‘‘no psychotic episodes,’’ ‘‘no impairment,’’ ‘‘good
to excellent social functioning,’’ etc. We agree that mortal-
ity is an important measure of outcome and that wherever
standardizedmortalityratios(SMRs)areavailable,people
with schizophrenia tend to have elevated rates, compared
with the general population. In the ISoS study,
5 SMRs
were calculated for 6 schizophrenia cohorts in developing
countries and 12 cohorts in developed countries. Of the 13
SMR values significant at P < .05, 4 were in developing
countriesand9indevelopedcountries.Allthe5highestval-
ues (SMR > 4.0) were in developed countries. Had Cohen
etal
1includedintheirreviewcomparabledatafromcourse
andoutcomestudiesinhigh-incomecountries,thecontrast
between the 2 groups of settings would be striking.
We do not argue that the prognosis of schizophrenia in
developing countries is groupwise uniformly milder or
that the existing huge gaps in mental health service pro-
vision between high- and low-income countries are irrel-
evant to the lives of millions of people affected by this
disorder. On the contrary, the erosion of social support
systems,likelytobeassociatedwiththeprocessesofglob-
alization,
12 should be a matter of grave concern. The
sobering experience of high rates of chronic disability
and dependency associated with schizophrenia in high-
income countries, despite access to costly biomedical
treatment, suggests that something essential to recovery
is missing in the social fabric. Thus, the existence of out-
come differentials between populations and cultures is
not ‘‘presumed wisdom’’ but a real complex issue which
shouldbeaddressedwithstandardsofprecisionandrigor
that are customary in scientific research and discourse.
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